This article was originally published in The Tan Sheet
Vineet Chhabra and his companies Dynamic Health of Florida and Chhabra Group are required to "rely on competent and reliable scientific evidence" to substantiate claims for their children's product Pedia Loss under a settlement reached with FTC, the commission announced April 6. FTC specifically pointed to claims that the product "suppresses appetite, increases fat burning and slows carbohydrate absorption." The marketers also are prohibited from making unsubstantiated claims for Fabulously Feminine, which they claimed would "increase a woman's libido, sexual desire and sexual satisfaction"...
You may also be interested in...
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Limiting interactions to two-dimensional settings will hinder collaboration, innovation and the mentoring of younger employees, Merck & Co. CEO Kenneth Frazier says. Frazier, who will retire in June, is looking forward to returning to public service but says "politics with a capital P is not my thing."